206 related articles for article (PubMed ID: 36930265)
21. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Escudier B; Porta C; Schmidinger M; Rioux-Leclercq N; Bex A; Khoo V; Gruenvald V; Horwich A;
Ann Oncol; 2016 Sep; 27(suppl 5):v58-v68. PubMed ID: 27664262
[No Abstract] [Full Text] [Related]
22. The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma.
Doehn C; Grünwald V; Steiner T; Follmann M; Rexer H; Krege S
Dtsch Arztebl Int; 2016 Sep; 113(35-36):590-6. PubMed ID: 27658472
[TBL] [Abstract][Full Text] [Related]
23. Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.
Califano R; Karamouzis MV; Banerjee S; de Azambuja E; Guarneri V; Hutka M; Jordan K; Kamposioras K; Martinelli E; Corral J; Postel-Vinay S; Preusser M; Porcu L; Torri V
Lung Cancer; 2014 Jul; 85(1):74-80. PubMed ID: 24746176
[TBL] [Abstract][Full Text] [Related]
24. The diagnostic challenges of patients with carcinoma of unknown primary.
Rassy E; Pavlidis N
Expert Rev Anticancer Ther; 2020 Sep; 20(9):775-783. PubMed ID: 32779501
[TBL] [Abstract][Full Text] [Related]
25. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions.
Varadhachary GR; Raber MN; Matamoros A; Abbruzzese JL
Lancet Oncol; 2008 Jun; 9(6):596-9. PubMed ID: 18510991
[TBL] [Abstract][Full Text] [Related]
26. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Escudier B; Eisen T; Porta C; Patard JJ; Khoo V; Algaba F; Mulders P; Kataja V;
Ann Oncol; 2012 Oct; 23 Suppl 7():vii65-71. PubMed ID: 22997456
[No Abstract] [Full Text] [Related]
27. Evidence-based clinical practice guidelines for renal cell carcinoma (Summary--JUA 2007 Edition).
Fujioka T; Obara W; ;
Int J Urol; 2009 Apr; 16(4):339-53. PubMed ID: 19416398
[TBL] [Abstract][Full Text] [Related]
28. Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma.
Goebell PJ; Ivanyi P; Bedke J; Bergmann L; Berthold D; Boegemann M; Busch J; Doehn C; Krege S; Retz M; Amsberg GV; Grimm MO; Gruenwald V
Future Oncol; 2020 Oct; 16(29):2307-2328. PubMed ID: 32964728
[TBL] [Abstract][Full Text] [Related]
29. Carcinoma of unknown primary (CUP): an update for histopathologists.
Beauchamp K; Moran B; O'Brien T; Brennan D; Crown J; Sheahan K; Cotter MB
Cancer Metastasis Rev; 2023 Dec; 42(4):1189-1200. PubMed ID: 37394540
[TBL] [Abstract][Full Text] [Related]
30. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Escudier B; Kataja V;
Ann Oncol; 2010 May; 21 Suppl 5():v137-9. PubMed ID: 20555064
[No Abstract] [Full Text] [Related]
31. [Breast-like cancer of unknown primary : Implications for radiological diagnostics].
Schneeweiss A; Buschhorn L
Radiologie (Heidelb); 2023 May; 63(5):366-370. PubMed ID: 36976360
[TBL] [Abstract][Full Text] [Related]
32. ESMO-Magnitude of Clinical Benefit Scale version 1.1.
Cherny NI; Dafni U; Bogaerts J; Latino NJ; Pentheroudakis G; Douillard JY; Tabernero J; Zielinski C; Piccart MJ; de Vries EGE
Ann Oncol; 2017 Oct; 28(10):2340-2366. PubMed ID: 28945867
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.
Zaun G; Borchert S; Metzenmacher M; Lueong S; Wiesweg M; Zaun Y; Pogorzelski M; Behrens F; Schildhaus HU; Virchow I; Kasper S; Schuler M; Theurer S; Liffers S
Eur J Cancer; 2024 Mar; 200():113540. PubMed ID: 38316065
[TBL] [Abstract][Full Text] [Related]
34. [WHO classification 2016 and first S3 guidelines on renal cell cancer: What is important for the practice?].
Moch H
Pathologe; 2016 Mar; 37(2):127-33. PubMed ID: 26942728
[TBL] [Abstract][Full Text] [Related]
35. [Update of the German S3 guideline on renal cell carcinoma].
Doehn C; Bergmann L; Decker J; Gauler T; Grünwald V; Weikert S; Krege S
Urologie; 2024 May; 63(5):439-447. PubMed ID: 38602533
[TBL] [Abstract][Full Text] [Related]
36. [Clinical recommendations for treating and monitoring patients with renal cancer].
Petković M; Vrdoljak E; Ruzić IP; Belev B; Omrcen T; Ledina D; Tomek R; Ruzić B; Situm M; Buća A; Pisac VP;
Lijec Vjesn; 2012; 134(1-2):5-8. PubMed ID: 22519246
[TBL] [Abstract][Full Text] [Related]
37. What Do International Guidelines Say About First-line Therapy for Clear-cell Metastatic Renal Cell Carcinoma?
Thana M; Wood LA
Eur Urol Focus; 2020 Jan; 6(1):48-52. PubMed ID: 31629680
[TBL] [Abstract][Full Text] [Related]
38. [Pathological diagnostics of CUP (Cancer of Unknown Primary)].
Tímár J
Magy Onkol; 2019 Jun; 63(2):67-74. PubMed ID: 31225529
[TBL] [Abstract][Full Text] [Related]
39. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.
Motzer RJ; Jonasch E; Boyle S; Carlo MI; Manley B; Agarwal N; Alva A; Beckermann K; Choueiri TK; Costello BA; Derweesh IH; Desai A; George S; Gore JL; Haas N; Hancock SL; Kyriakopoulos C; Lam ET; Lau C; Lewis B; Madoff DC; McCreery B; Michaelson MD; Mortazavi A; Nandagopal L; Pierorazio PM; Plimack ER; Ponsky L; Ramalingam S; Shuch B; Smith ZL; Somer B; Sosman J; Dwyer MA; Motter AD
J Natl Compr Canc Netw; 2020 Sep; 18(9):1160-1170. PubMed ID: 32886895
[TBL] [Abstract][Full Text] [Related]
40. Kidney cancer. Clinical practice guidelines in oncology.
Motzer RJ; Bolger GB; Boston B; Carducci MA; Fishman M; Hancock SL; Hauke RJ; Hudes GR; Jonasch E; Kantoff P; Kuzel TM; Lange PH; Levine EG; Logothetis C; Margolin KA; Pohar K; Redman BG; Robertson CN; Samlowski WE; Sheinfeld J;
J Natl Compr Canc Netw; 2006 Nov; 4(10):1072-81. PubMed ID: 17112454
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
